Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

CYTX Insider Trading

PLUS THERAPEUTICS, INC. | Surgical & Medical Instruments & Apparatus

Comprehensive Trading Performance Summary

The investment history of corporate insiders at PLUS THERAPEUTICS, INC. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Surgical & Medical Instruments & Apparatus sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2011-09-15 19:07 2011-09-14 HAWRAN PAUL W Director BUY $3.20 5,000 $15,992 71,610 +7.5%
2011-09-15 19:06 2011-09-14 RICKEY DAVID Director BUY $3.17 7,500 $23,805 38,559 +24.1%
2011-09-15 19:05 2011-09-14 Dean Lloyd H Director BUY $3.15 6,000 $18,890 15,000 +66.7%
2011-08-24 21:00 2011-08-19 HOLMES E CARMACK Director BUY $3.15 3,000 $9,450 27,401 +12.3%
2011-08-23 20:29 2011-08-19 Thompson Tommy G Director BUY $3.25 3,050 $9,921 24,050 +14.5%
2011-08-23 19:29 2011-08-22 RICKEY DAVID Director BUY $2.95 148 $437 31,059 +0.5%
2011-08-15 21:25 2011-08-12 RICKEY DAVID Director BUY $3.09 10,000 $30,874 30,911 +47.8%
2011-08-12 22:40 2011-08-12 Dean Lloyd H Director BUY $3.08 7,500 $23,082 9,000 +500.0%
2011-08-12 22:20 2011-08-12 HEDRICK MARC H Director, Officer - President BUY $3.19 2,500 $7,967 6,500 +62.5%
2011-08-12 21:36 2011-08-12 HENRIKSEN RONALD D Director BUY $3.09 2,000 $6,188 60,092 +3.4%
2011-08-12 21:34 2011-08-12 Saad Mark E Officer - Chief Financial Officer BUY $3.12 6,500 $20,290 122,500 +5.6%
2011-05-26 03:48 2011-05-20 Dean Lloyd H Director BUY $5.27 1,500 $7,907 1,500 +100.0%
2010-12-24 01:56 2010-12-22 CALHOUN CHRISTOPHER J Director, Officer - Chief Executive Officer SELL $5.69 48,125 $273,908 83,125 -36.7%
2010-06-07 22:46 2010-06-04 SHIRAHAMA NORIO SEIJIRO Officer - President - Asia Pacific BUY $4.57 1,500 $6,855 10,200 +17.2%
2010-05-24 20:36 2010-05-24 HAWRAN PAUL W Director BUY $4.65 5,000 $23,235 60,610 +9.0%
2010-05-21 21:35 2010-05-21 Saad Mark E Officer - Chief Financial Officer BUY $4.29 6,000 $25,741 82,500 +7.8%
2010-05-20 02:40 2010-05-19 HAWRAN PAUL W Director BUY $4.83 5,000 $24,164 55,610 +9.9%
2010-01-22 04:22 2010-01-20 HOLMES E CARMACK Director OPT+S $9.06 20,000 $181,256 2,472 0.0%
2009-11-25 22:44 2009-11-25 HAWRAN PAUL W Director BUY $4.90 5,000 $24,500 49,316 +11.3%
2009-11-25 02:12 2009-11-24 HAWRAN PAUL W Director BUY $4.74 5,000 $23,700 44,316 +12.7%
2009-11-19 02:30 2009-11-18 HAWRAN PAUL W Director BUY $4.25 20,000 $84,900 39,316 +103.5%
2009-11-18 02:15 2009-11-17 HAWRAN PAUL W Director BUY $3.98 5,000 $19,900 19,316 +34.9%
2009-11-13 01:07 2009-11-12 HAWRAN PAUL W Director BUY $3.50 10,000 $35,000 14,316 +231.7%
2009-05-21 02:30 2009-05-20 CALHOUN CHRISTOPHER J Director, Officer - Chief Executive Officer BUY $2.92 6,600 $19,272 36,850 +21.8%
2009-05-19 23:49 2009-05-19 CALHOUN CHRISTOPHER J Director, Officer - Chief Executive Officer BUY $2.99 3,250 $9,718 30,250 +12.0%
2009-05-19 02:40 2009-05-15 CALHOUN CHRISTOPHER J Director, Officer - Chief Executive Officer BUY $2.81 7,000 $19,700 27,000 +35.0%
2009-05-12 03:03 2009-05-07 RICKEY DAVID Director BUY $2.28 4,386 $10,000 13,235 +49.6%
2009-05-12 03:02 2009-05-07 HENRIKSEN RONALD D Director BUY $2.28 22,000 $50,160 50,524 +77.1%
2009-05-12 03:01 2009-05-07 HEDRICK MARC H Director, Officer - President BUY $2.28 20,000 $45,600 448,238 +4.7%
2008-12-02 03:08 2008-11-26 SHIRAHAMA NORIO SEIJIRO Officer - President - Asia Pacific BUY $1.92 2,500 $4,800 8,700 +40.3%
2008-11-24 14:03 2008-11-21 RICKEY DAVID Director BUY $1.96 17,500 $34,225 34,909 +100.5%
2008-11-21 05:14 2008-11-20 RICKEY DAVID Director BUY $2.06 13,449 $27,720 29,909 +81.7%
2008-11-19 01:36 2008-11-17 HENRIKSEN RONALD D Director BUY $2.66 5,000 $13,285 23,161 +27.5%
2008-10-15 03:05 2008-10-10 HENRIKSEN RONALD D Director SELL $3.12 4,000 $12,471 0 -100.0%
2008-10-15 03:05 2008-10-09 HENRIKSEN RONALD D Director BUY $3.81 4,000 $15,240 4,000 +100.0%
2008-08-14 21:20 2008-08-12 HEDRICK MARC H Director, Officer - President BUY $6.71 11,800 $79,191 7,800 +100.0%
2008-08-12 23:25 2008-08-12 Saad Mark E Officer - Chief Financial Officer BUY $6.69 15,000 $100,310 76,500 +24.4%
2008-08-12 03:26 2008-08-07 OLYMPUS CORP 10% owner BUY $6.00 1,000,000 $6,000,000 4,013,043 +33.2%
2008-06-11 02:03 2008-06-10 CALHOUN CHRISTOPHER J Director, Officer - Chief Executive Officer OPT+S $8.34 53,190 $443,780 100,000 0.0%
2007-08-25 02:09 2007-08-22 CALHOUN CHRISTOPHER J Officer - Chief Executive Officer SELL $5.26 50,000 $263,000 100,000 -33.3%
2006-12-15 02:35 2006-12-14 CALHOUN CHRISTOPHER J Officer - Chief Executive Officer BUY $5.06 6,000 $30,375 20,000 +42.9%
2006-12-13 20:20 2006-12-13 CALHOUN CHRISTOPHER J Officer - Chief Executive Officer BUY $4.87 6,000 $29,220 14,000 +75.0%
2006-12-12 00:35 2006-12-11 CALHOUN CHRISTOPHER J Officer - Chief Executive Officer BUY $4.77 4,000 $19,099 8,000 +100.0%
2006-12-09 04:55 2006-12-08 CALHOUN CHRISTOPHER J Officer - Chief Executive Officer BUY $4.65 4,000 $18,590 4,000 +100.0%
2006-12-01 02:35 2006-11-28 HEDRICK MARC H Officer - President BUY $4.29 10,000 $42,862 428,238 +2.4%
2006-11-29 03:35 2006-11-24 HEDRICK MARC H Officer - President BUY $4.36 5,500 $23,995 418,238 +1.3%
2006-11-23 01:38 2006-11-21 SHIRAHAMA NORIO SEIJIRO Officer - Senior Vice President Asia Pac BUY $4.20 2,000 $8,400 4,200 +90.9%
2006-11-23 01:32 2006-11-21 HEDRICK MARC H Officer - President BUY $4.12 2,213 $9,120 412,738 +0.5%
2006-09-12 02:25 2006-09-07 Milstein Alexander M Officer - Vice President Clinical Develo BUY $4.50 400 $1,800 1,200 +50.0%
2006-09-08 01:51 2006-09-05 Saad Mark E Officer - Chief Financial Officer BUY $5.08 1,850 $9,393 61,500 +3.1%
SHOW ENTRIES

How to Interpret $CYTX Trades

Not every insider transaction in PLUS THERAPEUTICS, INC. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $CYTX shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for CYTX

Insider activity data for PLUS THERAPEUTICS, INC. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $CYTX, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.